1 clinic
100charts
For medical directors, CMOs & clinic owners
Complete oversight of every chart.
We help medical directors catch dangerous care in unreviewed charts by ranking every flagged case with its evidence, so they can stop harm before it reaches patients or the practice.
- Sourced reasoning on every flag. The call stays with medical leadership.
Built for specialty clinics
Weight management & Metabolic
Hormone health
ADHD & Psychiatry
Fertility
and more
The Anatomy Lesson of Dr. Nicolaes Tulp
Best score on that chart set. The same construction works for any treatment sequence.
How the benchmark is built
HIPAA
100%
of 2.52 million labels
Verdicts
$56M
average of the 50 largest in 2024
Identifiers removed before review. Privacy-first by design.
Safe Harbor de-identification
$32M in 2022. $48M in 2023.
The Doctors Company and AMA
Peer review 1–5% of admissions, weeks to monthsThat is the surveyed hospital range. The license still covers every chart.
National U.S. hospital peer-review survey
EHR 11 named systems from the batEpic, Cerner, athena, eCW, and seven more. One encounter object for every product we ship next.
Read-only · no write-back
The oversight gap
You sign for every chart. Now you can see them.
One busy site can produce more charts than a medical director can reasonably read. Across more sites and prescribers, each team builds its own filter for what gets reviewed. The result is incomplete visibility and inconsistent oversight.
Platform
Scales with your organization’s charts.
100 clinics
10,000charts
One site or a hundred. Every chart is screened. Leadership gets a ranked list with sourced reasoning on each flag. Detail belongs on a call or demo.
How it flags
Every flag comes with its evidence.
Each flag shows sourced reasoning and a link to the official source. The clinical call stays with the director.
Example flags
Why this was flagged
Semaglutide started. Family history of medullary thyroid carcinoma is in the note. The label contraindicates that.
personal or family history of MTC
Matched in chart
“Mother with medullary thyroid carcinoma. Start Ozempic 0.25 mg weekly.”
Source
Guideline cited
“OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”
DailyMed / FDA SPL, boxed warning.
dailymed.nlm.nih.gov
Warning: risk of thyroid C-cell tumors
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Why this was flagged
Semaglutide started. The note has no BMI. Eligibility for a GLP-1 is judged on BMI. The director opens the ADA Standards of Care page.
BMI not recorded
Matched in chart
“BMI not recorded. Start semaglutide 0.25 mg weekly.”
Source
Guideline cited
Official source page. The director opens the version of record.
ADA Standards of Care and peer society guidance.
professional.diabetes.org
ADA Standards of Care in Diabetes
The official landing is the citation. Rubik does not copy the society PDF.
Why this was flagged
Compounded tirzepatide is recorded as the same as the approved drug. The FDA page names that claim as a warning sign.
Matched in chart
“Compounded tirzepatide 5 mg weekly. Same as Mounjaro.”
Source
Guideline cited
“A compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available. However, compounded drugs are not FDA approved.”
FDA drug alert, content current as of 09/01/2026.
fda.gov
Unapproved GLP-1 drugs used for weight loss
Compounded drugs are not FDA approved. Claiming a compounded drug is the same as an approved drug is a warning sign.
Why this was flagged
The note records obesity counseling with no other diagnosis. NCD 100.1 keeps treatments for obesity alone non-covered.
obesity · no other diagnosis
Matched in chart
“Obesity counseling visit. No other diagnosis. RTC 3 months.”
Source
Guideline cited
“Non-surgical services in connection with the treatment of obesity are covered when such services are an integral and necessary part of a course of treatment for one of these medical conditions. Treatments for obesity alone remain non-covered.”
CMS NCD 100.1, v5.
cms.gov
Bariatric Surgery for Treatment of Co-Morbid Conditions Related to Morbid Obesity
Treatments for obesity alone remain non-covered.
Why this was flagged
Wegovy started at BMI 26.2. Rec 17 is BMI ≥30, or BMI ≥27 with an obesity-associated condition. 26.2 is below both floors.
BMI 26.2 · below Rec 17
Matched in chart
“BMI 26.2. Start Wegovy 0.25 mg weekly.”
Source
Guideline cited
“We recommend semaglutide or tirzepatide for both weight loss and to maintain weight loss, in conjunction with a comprehensive lifestyle intervention, in patients with a body mass index ≥27 kg/m² who also have an obesity-associated condition; and those who have a body mass index ≥30 kg/m².”
VA/DoD Obesity CPG 2025 Provider Summary, Recommendation 17.
healthquality.va.gov
Management of Adult Overweight and Obesity
Recommendation 17: semaglutide or tirzepatide at BMI ≥30, or BMI ≥27 with an obesity-associated condition.
Walkthrough
From 200 encounters to the 12 that need review.
Example queue
Start with the exceptions that need a look.
From a full cohort to a short prioritized list for directors. Every flag comes with sourced reasoning. The call stays with clinical leadership.
| Review scope | Count | Result |
|---|---|---|
| Encounters screened | 200 | Full cohort |
| Cases flagged | 12 | Prioritized |
| High priority | 6 | Review first |
Caught in the note
Treatment moved forward. The baseline workup did not.
Before and after
From a small sample to organization-wide visibility.
Rubik MD gives medical leadership a clearer view of the care actually being delivered across every location and program.
| Dimension | Without Rubik MD | With Rubik MD |
|---|---|---|
| Coverage | A small sample selected manually. | Every chart screened. |
| Focus | Leadership must decide where to look. | Cases that need judgment are prioritized, with the reason attached. |
| Evidence | The reviewer reconstructs the issue from the chart. | The flagged sentence and the reason arrive on the same screen. |
| Review record | Review notes vary by person and location. | The decision and rationale are recorded consistently. |
FAQ
Straight answers for the people who sign for care.
The practical questions buyers ask before booking a call.
What does Rubik MD check charts against?
Rubik MD reads the visit note and looks for a medical error in that note. Every flag shows the flagged sentence, a short reason, and the source page: DailyMed boxed warning, ADA Standards of Care, FDA unapproved GLP-1 alert, CMS NCD 100.1, or VA/DoD obesity CPG. The director confirms or dismisses it.
Does Rubik MD make clinical decisions?
No. Rubik MD is read-only. It surfaces cases and evidence for clinical leadership; it does not diagnose, prescribe, recommend treatment, or write back into the chart.
What does implementation require?
We begin with one site and read-only access. No change to the treating clinician’s workflow. A director list follows. Implementation detail is on the call.
What happens to our data?
Charts are de-identified before Rubik sees them. Directors review flagged cases with sourced reasoning. Lists are not kept longer than needed. Full privacy detail is on the call or demo.
Is Rubik MD HIPAA compliant?
Yes. Designed for HIPAA Safe Harbor de-identification before any data reaches Rubik. Clinical judgment stays with leadership. The full privacy architecture is part of every demo.
How do you manage false positives and misses?
Rubik MD prioritizes cases by risk and uncertainty and shows the evidence behind every flag. Clinical leadership confirms or dismisses each one. Performance is evaluated on your charts and your confirm-or-dismiss decisions during the pilot.
Book a short demo.
A 30-minute call with the founding team. We walk the director list and how a pilot would run.